GVBP’s target market - cancer treatments - is the largest disease market, exploding at a 20% growth rate each year!

GVBP’s treatment niche is based on recent discoveries that indicate that most tumors are derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell).

GVBP has chosen to concentrate on identification of certain cell-specific characteristics, making it possible to identify precursor cells of tumors, and then conduct a more extensive ‘fingerprinting’ profile that will enable the development of cell-specific anti-cancer treatments.

This will result in a ‘tailor made’ cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.

Stem cells offer exciting promise in the medical world.

According to Visiongain new report Stem Cells - The Hype & Hope - World Analysis 2009-2024 - Stem cells represent one of the most promising medical breakthroughs of all time!

Click here to read the article: http://www.pr.com/press-release/155102

Earlier this year President Obama overturned the Bush policy on stem cell research and has lifted the ban on federal funding of promising stem cell research!

“Medical miracles do not happen simply by accident,” Obama has declared.

GVBP’s new stem cell identification technology could cure breast cancer!

GVBP Vice President John Savin stated, “GENova’s approach is based on cutting-edge technology that enables us to identify the protein expression in the original cancer stem cells that give rise to tumors. This ability to identify the molecular markers of these cells is an important first step in developing new and superior cancer cures. By recognizing the existence of cancer stem cells, we have taken a great step towards understanding this complex disease. Now that we know how to identify the unique characteristics of these stem cells, we can develop cell-specific therapies that can eradicate them –and thus neutralize breast cancer right at the source.”

The key behind GVBP’s biotechnology is tracing cancer cells to their origin, the very stem cells from where the first malignant cell arose.

Now that they are identifiable, scientists are developing tailor-made proteins that are programmed to destroy cancerous cells, whilst leaving the healthy cells intact.

GVBP has targeted these bio-engineered proteins for acquisition into its growing anti-cancer drug pipeline.

Cancer represents the largest disease market, and has an explosive growth rate of 20% per annum!

Of the types of cancer, prostate cancer represents the largest market and breast cancer the second!

GVBP currently has 2 developmental drugs in their pipeline. One targets breast cancer called Tetanolic acid, and the other targets prostate cancer called Prostaganin.

Worldwide, breast cancer is the fifth most common cause of cancer death!

In the U.S. Statistically, women in the U.S. have a 1 in 8 lifetime risk of developing invasive breast cancer.